A drug initially designed to treat heart conditions took an unexpected turn in the early 1990s when it was found to have a different, more impactful use. The molecule, known as UK-92480, was developed by Pfizer in Sandwich, a small town in southeast England, as part of research aimed at treating angina, a condition characterized by chest pain due to reduced blood flow to the heart. The drug targeted the phosphodiesterase type 5 (PDE5) enzyme, which plays a role in the relaxation of smooth muscles in blood vessels. Researchers hoped that by blocking PDE5, they could help widen coronary arteries and ease chest pain. In 1991, Phase I clinical trials tested oral doses of up to 200 milligrams on healthy volunteers. While the drug did cause blood vessels to widen, the effect was considered too mild to be useful for treating angina. However, researchers noticed that male participants experienced unexpected side effects, including spontaneous and prolonged erections. These findings, though initially unintended, prompted a shift in the drug’s development strategy. Rather than discarding the molecule, Pfizer decided to focus on the newfound potential for treating erectile dysfunction. The drug was patented in 1996 and later approved by the U.S. Food and Drug Administration (FDA) in 1998 under the name Viagra. European regulatory agencies approved it in 1999. Sildenafil, the active ingredient in Viagra, became the first effective oral treatment for erectile dysfunction, addressing a medical need that had long gone unmet. The success of Viagra far surpassed what was initially anticipated, making it one of the most commercially successful drugs of the late twentieth century. The story of sildenafil underscores how scientific research can lead to unexpected breakthroughs, as what was once considered a dead-end in heart disease treatment became a major advancement in sexual health.